An occupational exposure limit (OEL) approach to protect home healthcare workers exposed to common nebulized drugs

被引:12
作者
Frank, Evan [1 ]
Ishau, Simileoluwa [1 ]
Maier, Andrew [2 ]
Reutman, Susan [3 ]
Reichard, John F. [1 ]
机构
[1] Univ Cincinnati, Coll Med, Dept Environm Hlth, 160 Panzeca Way, Cincinnati, OH 45267 USA
[2] Univ Cincinnati, Coll Med, Dept Environm Hlth & Cardno ChemRisk, Cincinnati, OH 45267 USA
[3] Univ Cincinnati, Coll Nursing, Cincinnati, OH 45267 USA
关键词
Nebulizer; Albuterol; Ipratropium; Budesonide; Acceptable daily exposure or OEL; Pharmaceutical risk assessment; METERED-DOSE INHALER; IPRATROPIUM BROMIDE; FLUTICASONE PROPIONATE; SALBUTAMOL ENANTIOMERS; RELATIVE LUNG; DRY POWDER; PHARMACOKINETICS; BUDESONIDE; INHALATION; ASTHMA;
D O I
10.1016/j.yrtph.2019.04.021
中图分类号
DF [法律]; D9 [法律]; R [医药、卫生];
学科分类号
0301 ; 10 ;
摘要
Home healthcare is a growing area of employment. Assessment of occupational health risks to home health care workers (HHCWs) is important because in many cases the unique characteristics of the home environment do not facilitate the level of exposure control afforded to caregivers in hospitals and other fixed patient care sites. This assessment is focused on health risks to HHCWs from exposure to pharmaceutical drugs used to treat asthma and other respiratory diseases, which are commonly administered to patients in aerosolized form via nebulizers. We developed risk-based exposure limits for workers in the form of occupational exposure limits (OEL) values for exposure to nebulized forms of the three most common drugs administered by this method: albuterol, ipratropium, and budesonide. The derived OEL for albuterol was 2 mu g/day, for ipratropium was 30 mu g/day, and for budesonide was 11 mu g/day. These OELs were derived based on human effect data and adjusted for pharmacokinetic variability and areas of uncertainty relevant to the underlying data (human and non-human) available for each drug. The resulting OEL values provide an input to the occupational risk assessment process to allow for comparisons to HHCW exposure that will guide risk management and exposure control decisions.
引用
收藏
页码:251 / 261
页数:11
相关论文
共 60 条
  • [1] The use of ipratropium bromide for the management of acute asthma exacerbation in adults and children: A systematic review
    Aaron, SD
    [J]. JOURNAL OF ASTHMA, 2001, 38 (07) : 521 - 530
  • [2] OCCUPATIONAL EXPOSURE LIMITS FOR THERAPEUTIC SUBSTANCES
    AGIUS, R
    [J]. ANNALS OF OCCUPATIONAL HYGIENE, 1989, 33 (04) : 555 - 562
  • [3] AstraZeneca, 2016, MSDS PULM RESP
  • [4] AstraZeneca, 2017, PROD MON PULM NEB
  • [5] Exposure of health care workers to pentamidine isethionate
    Beach, JR
    Campbell, M
    Andrews, DJ
    [J]. OCCUPATIONAL MEDICINE-OXFORD, 1999, 49 (04): : 243 - 245
  • [6] BELL JA, 1984, MT SINAI J MED, V51, P215
  • [7] Comparative study of budesonide as a nebulized suspension vs pressurized metered-dose inhaler in adult asthmatics
    Bisgaard, H
    Nikander, K
    Munch, E
    [J]. RESPIRATORY MEDICINE, 1998, 92 (01) : 44 - 49
  • [8] RELATIVE AMOUNT OF ALBUTEROL DELIVERED TO LUNG RECEPTORS FROM A METERED-DOSE INHALER AND NEBULIZER SOLUTION - BIOASSAY BY HISTAMINE BRONCHOPROVOCATION
    BLAKE, KV
    HOPPE, M
    HARMAN, E
    HENDELES, L
    [J]. CHEST, 1992, 101 (02) : 309 - 315
  • [9] Boehringer Ingelheim Ltd, 2010, ATROV UDV INH SOL PR
  • [10] Comparative adrenal suppression with inhaled budesonide and fluticasone propionate in adult asthmatic patients
    Clark, DJ
    Grove, A
    Cargill, RI
    Lipworth, BJ
    [J]. THORAX, 1996, 51 (03) : 262 - 266